Medical/Pharmaceuticals
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...
2025-08-19 13:26
1723
Tigermed Receives MSCI ESG AAA Rating
HANGZHOU, China, Aug. 18, 2025 /PRNewswire/ -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us a...
2025-08-19 11:15
2216
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
* Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] * In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisation...
2025-08-19 11:00
2446
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary o...
2025-08-19 08:00
1900
openRxiv names Dr. Tracy Teal first CEO to advance open science
Scientist and nonprofit leader who previously led The Carpentries and Dryad to lead the organization that oversees bioRxiv and medRxiv. DAVIS, Calif., Aug. 19, 2025 /PRNewswire/ -- openRxiv announced today that after an extensive international search, its Board of Directors has appointed Dr.Trac...
2025-08-19 00:00
1403
Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform
Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings DUBLIN, Aug. 18, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, today ann...
2025-08-18 21:30
2349
Datasea Achieves Breakthrough in Acoustic Technology, Accelerating Billion-Dollar Commercialization in Healthcare
DTSS' Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed$100 Billion in China and Approach $90 Billion Globally by 2030 BEIJING, Aug. 18, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology enterprise specializin...
2025-08-18 21:30
2763
Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
* This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. * DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South...
2025-08-18 21:00
1761
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
2025-08-18 20:00
2483
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
* Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion * Research and development expenses was approximately RMB611.5 million * Loss for the period was RMB145.2 million; adjusted loss for the period[1] ...
2025-08-18 18:29
2271
India's leading healthcare network Manipal Hospitals welcomes India's leading cancer specialist Dr. Surender Kumar Dabas to strengthen robotic cancer care in Delhi NCR
NEW DELHI, Aug. 18, 2025 /PRNewswire/ -- Manipal Hospitals, one of India's
leading and globally recognized healthcare institutions, welcomes one ofIndia's
most renowned robotic oncosurgeons, Dr. Surender Kumar Dabas
2025-08-18 18:23
1392
GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies
YONGIN, South Korea, Aug. 18, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the production of plasma-deri...
2025-08-18 12:40
1500
Next Generation Refractive Surgery to LASIK and SMILE Now Available for Clinical Review
Pioneer surgeon Dr Natasha Lim is among the first in Singapore to offer Smooth Incision Lenticular Keratomileusis (SILK) procedure in their clinics. SINGAPORE, Aug. 18, 2025 /PRNewswire/ -- Dr. Natasha Lim, an internationally renowned surgeon in Ophthalmology, has introduced an alternative to est...
2025-08-18 11:00
1665
New support group to provide social and community support for neurofibromatosis patients
Co-founded by individuals living with this rare genetic condition, the Neurofibromatosis Society Singapore seeks to close gaps in mental and emotional care SINGAPORE, Aug. 18, 2025 /PRNewswire/ -- A new patient-led support group, the Neurofibromatosis Society (NFS)Singapore, has been recently re...
2025-08-18 09:00
1774
Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
- Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting bothGLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) mouse model. - Combination of a low dose of ASC47 with A...
2025-08-18 08:15
1772
GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the ...
2025-08-17 20:01
2287
VARON's Lung Health Awareness Initiative Urges Proactive Steps for Allergy and Flu this Fall Season
NEW YORK, Aug. 15, 2025 /PRNewswire/ -- With allergy and flu season
approaching, VARON
2025-08-15 23:08
2473
Novel Gene Therapy for ALS cleared for global trials in China and the U.S.
BEIJING, Aug. 15, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today thatChina's National Medical Products Administration (NMPA) has cleared the Investigational...
2025-08-15 19:00
1772
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that etrasimod (VELSIPITY®) has be...
2025-08-15 09:35
2044
CARsgen Therapeutics Announces 2025 Interim Results
SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results. Business Highlights * Cash and bank balances were around RMB1,261 million as of June 30,...
2025-08-15 08:15
2686
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 275 media titles]
2025-12-26 12:55The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup
[Picked up by 270 media titles]
2025-12-21 12:42
Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 263 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54